Navigation Links
New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
Date:5/18/2008

Additional Digestive Disease Week data highlight effects of AMITIZA in

patients with IBS-C

SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists.

"IBS-C is a multi-symptom disorder and is one of the most common conditions seen by gastroenterologists," said William D. Chey, M.D., primary investigator of the study, University of Michigan Health System. "These data are important because they show that in studies, AMITIZA has demonstrated the ability to improve the overall symptoms reported by patients with IBS-C."

AMITIZA 8 mcg was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2008 for the treatment of IBS-C in women 18 years of age and older, and has been approved since 2006 at a 24 mcg dose for the treatment of Chronic Idiopathic Constipation in adults. These data were among others presented at DDW 2008 that evaluated the effect of AMITIZA for IBS-C.

"AMITIZA is the first ClC-2 channel activator and the only widely available FDA-approved agent for the treatment of IBS-C in adult women in the United States. AMITIZA could provide overall symptom relief for the millions of appropriate patients in the U.S. who suffer from this condition," said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals (Nasdaq: SCMP). "We are pleased with the body of data on AMITIZA presented at DDW this year. Additional data presented at thi
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals,
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
5. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
6. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
7. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
9. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
10. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... and LONDON , December ... orthopedic industry are expected to grow at an average ... terms of value and volume. Hip, knee and spine ... world while in emerging economies they have a lower ... are challenging the use of composites. Non-metallic orthopedic devices ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Facial Plastic Surgeon, Davis B. Nguyen, MD is ... ARTISS Fibrin Sealant has been approved by the FDA ... seven prominent plastic surgeons in the country who, in ... the benefits of using fibrin glue in facelifts. ...
... Galenea Corp., a leader in the rapidly emerging ... a paper in PLoS ONE demonstrating the ... Assay) system, Galenea,s proprietary technology that enables high throughput ...  Changes in synaptic function are now believed to play ...
Cached Medicine Technology:Facial Plastic Surgeon, Dr. Davis B. Nguyen Announces Fibrin Glue Approved by FDA for Use In Facelifts 2Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function 2Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function 3
(Date:12/26/2014)... Cooking and warming equipment has ... This score reflects slightly positive negotiation conditions for buyers, ... switching costs and a low level of price volatility. ... of substitutes for cooking and warming equipment and high ... key inputs in the production process of this equipment,” ...
(Date:12/26/2014)... “Many people become overwhelmed by the thought of ... phone calls with insurance companies,” The Jones Firm explains ... free eBook on pedestrian and bicycle accidents . ... auto accident claims assures the injured individual that a ... their case while they focus on recovering. , ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... A child spikes a high fever, sometimes as high as ... to the emergency room, the hospital runs test after test, ... Many families though no one knows how many ... like clockwork, arent accompanied by any obvious symptoms and dont ...
... Edward G.,Rendell today released the text of his March ... for MCare fund assessment payments:, Dear Health Care ... the state was in a unique,position to extend MCare ... affordable health care for hundreds of thousands of uninsured,Pennsylvanians., ...
... E.,Lattman, currently Dean of Research and Graduate Education in ... Hopkins University (JHU), has,been appointed Chief Executive Officer and ... assume the,position on July 1, 2008. A published author ... and JHU and at JHU has served,as department chair ...
... However, patients stay on the new medications longer, study ... so-called second-generation antipsychotics are no better than the older ... a new study finds. , However, it appears that ... likely to continue using them than haloperidol, the study ...
... 28 The Raleigh County League of,Democratic Women will ... on,presidential candidates Hillary Clinton and Barack Obama., "We,re ... Susman said. "But each one will be represented by ... 1 debate will be held at 6 p.m. Tuesday ...
... 16 multi-detector CT (MDCT); theres no need for an additional ... by researchers at the University of Maryland Medical Center and ... The study showed that whole body MDCT is just as ... blunt trauma patients would undergo whole-body MDCT and if there ...
Cached Medicine News:Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Whole body MDCT just as 'good' as neck MDCT angiography in diagnosing head and neck injuries 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: